Emofast 8 mg (Tablet)
Unit Price: ৳ 10.00 (3 x 10: ৳ 300.00)
Strip Price: ৳ 100.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Ondansetron |
| Company | Albion laboratories limited |
Therapeutic Class
- Anti-emetic drugs
Indications
- Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy
- Prevention and treatment of post-operative nausea and vomiting
- Prevention of radiotherapy-induced nausea and vomiting
Description
- Emofast oral soluble film is an orally dissolving film
- Designed to be applied on top of the tongue
- Dissolves within 20 seconds
- Active ingredient: Emofast base, a selective blocking agent of the serotonin 5-HT3 receptor type
- Empirical formula: C18H19N3O
- Molecular weight: 293.3
Pharmacology
- Ondansetron is a highly selective 5HT3 receptor-antagonist
- Mode of action in the control of nausea and vomiting is not fully known
- Blocks initiation of vomiting reflex by activating vagal afferents via 5HT3 receptors
- May also promote emesis through a central mechanism
- Antagonizes 5HT3 receptors in both peripheral and central nervous system
Dosage
- Adults, pediatric patients (6 months to 18 years)
- Injection and orodispersible tablet options available
- Specific dosages for highly emetogenic cancer chemotherapy and moderately emetogenic cancer chemotherapy
- Different dosages for adults and pediatric patients
- Dosage adjustments for patients with impaired renal function and impaired hepatic function
- Storage conditions: Not exceeding 30°C, in a dry place, protect from light and moisture
Administration
- Step-by-step administration guide for Oral Soluble Film
- Tear the pouch carefully
- Put the film on top of the tongue
- Do not chew or swallow the film whole
- Swallow after the film dissolves
- Wash hands after administration
Interaction
- Emofast does not induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the liver
- Metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes
- Inducers or inhibitors of these enzymes may change the clearance and half-life of Emofast
Contraindications
- Contraindicated in patients known to have hypersensitivity to the drug or any of its components
- Concomitant use of apomorphine
Side Effects
- Frequently reported adverse events: headache, constipation, diarrhea
- Rash occurred in approximately 1% of patients receiving Emofast
- Other reported side effects: sensation of flushing or warmth, hiccups, liver enzyme abnormalities
- Rare cases of anaphylaxis, bronchospasm, tachycardia, angina, hypokalemia, shortness of breath
- No evidence of extrapyramidal reactions
- Rates of adverse events in Emofast and placebo groups
Pregnancy & Lactation
- Carcinogenic effects were not seen in 2-year studies in rats and mice
- Ondansetron was not mutagenic in standard tests for mutagenicity
- No evidence of impaired fertility or harm to the fetus due to Ondansetron
- No adequate and well-controlled studies in pregnant women
- Ondansetron is excreted in the breast milk of rats
- Caution should be exercised when administered to nursing women
Precautions & Warnings
- Hypersensitivity reactions reported in some patients
- Emofast is not a drug that stimulates gastric or intestinal peristalsis
- Should not be used instead of nasogastric suction
- Use in patients following abdominal surgery or with chemotherapy-induced nausea and vomiting may mask a progressive ileus and/or gastric distension
Use in Special Populations
- Dosage adjustment for patients with impaired renal function
- Dosage adjustment for patients with impaired hepatic function
- Little information available about dosage in pediatric patients 4 years of age or younger
- No dosage adjustment needed in patients over the age of 65